KO — The Coca-Cola Company

Sentiment is clearly positive. Q2 2026 (reported 2026-07-28) delivered revenue of $13.38B, +6.7% YoY and above the ~$13.17B consensus, organic revenue +6% and global unit case volume +5%, and management raised FY2026 guidance to ~5% organic revenue growth and 9-10% comparable EPS growth. Sell-side followed: Jefferies to $104, TD Cowen to $100, Argus to $97, RBC and JPMorgan to $96, against a $95.75 consensus target and a 29 Buy / 16 Hold / 3 Sell rating split. The deeper driver is sector rotation - with a 0.342 beta and heavy cash generation, KO has been a destination for capital fleeing AI-capex anxiety in big tech, which is why a staples name has outrun the S&P 500 this year. As of 2026-09-13 the tape is not stretched (RSI 51.49, price -0.89% vs its 20-day SMA), so this is a story-driven re-rating rather than a momentum blow-off.

The trend inflected hard positive over the last six quarters and this is not a blip. Revenue YoY went -0.8% (Q3 2024), -1.5% (Q1 2025), +1.4% (Q2 2025), +5.1% (Q3 2025), +2.4% (Q4 2025), then +12.1% (Q1 2026, $12.47B) and +6.7% (Q2 2026, $13.38B). Operating margin stepped up from a 18.9-27.4% band across 2023-2024 to 32.9% / 34.1% / 32.0% / 35.0% / 34.9% in the last five reported quarters - a structural level shift, not noise, and consistent with the asset-right refranchising strategy. The one exception is Q4 2025, where operating income of $1.841B on $11.82B revenue implies only a 15.6% margin while net income was $2.271B - net income exceeding operating income means large below-the-line items, so treat that quarter as a one-off distortion rather than an operating deterioration. EPS is accelerating on the same path: $0.88 (Q2 2025) to $0.91 (Q1 2026) to $1.03 (Q2 2026, +17% YoY). Free cash flow is lumpy by quarter (Q1 2025 was -$5.51B, Q1 2026 +$1.76B; Q2 2026 +$5.10B) but TTM FCF is ~$14.3B on TTM operating cash flow of $16.34B, and the accruals ratio of -1.02% as of 2026-07-03 confirms reported earnings are backed by cash, not paper. Verdict: revenue re-accelerating, margins structurally higher, earnings quality clean.

Fair-to-full, not cheap. As of 2026-09-13 the trailing P/E was 26.51x versus a 5-year average of 25.4x (~4% premium), and price/sales was 7.58x versus a 5-year average of 6.11x - a 24% premium on that metric, which is the real evidence behind the deterministic model's 'Rich vs. its own history' label. P/B is 10.51x, PEG is 1.50, and the 2.57% dividend yield sits below where KO has historically yielded. The counter-argument: the FMP 'next FY' EPS estimate of $3.305 is essentially flat versus TTM EPS of $3.328, which is stale - it conflicts with management's own +9-10% comparable EPS guidance. Roll that guidance forward and FY2027 EPS lands near $3.60, putting the stock at ~24.5x 2027E, only a modest premium to staples peers and roughly in line with KO's own history. So the honest read is: no longer cheap on trailing numbers, but not wildly expensive if the guidance is delivered.

At $88.29, the market is paying 26.5x trailing EPS of $3.328 and ~24.5x my $3.60 FY2027E, so the stock is pricing in delivery of management's 9-10% comparable EPS growth, not heroics. The important wrinkle is that the widely-quoted 'next FY' EPS figure of $3.305 understates the trajectory - it implies zero growth off the trailing number, which is inconsistent with a company that just raised guidance. So if you screen KO on that stale estimate you will wrongly conclude the stock is expensive relative to flat earnings; the earnings power is there, and the risk is not that EPS disappoints but that the multiple has already done its work. The practical playbook: upside from here should track EPS growth plus the dividend (~10-12% annualized) rather than another leg of multiple expansion. Analyst consensus of $95.75 implies ~8.5% upside, and that is roughly the level of the 52-week high of $92.49 plus one more earnings step - i.e., PTs are assuming the multiple holds. A single quarter where volume growth slips below ~3% would likely compress the multiple 10%+ faster than EPS can offset.

Constructive but mid-trend, with no timing edge. As of 2026-09-13, RSI(14) was 51.49 - dead neutral, neither overbought nor oversold. Price of $88.29 sat -0.89% below the 20-day SMA (~$89.08), +2.01% above the 50-day SMA (~$86.55), and +12.08% above the 200-day SMA (~$78.78). Returns of +0.25% (1 week), +1.82% (1 month), +6.86% (3 months) and +14.16% (6 months) describe a steady, low-volatility uptrend now consolidating just beneath the 52-week high of $92.49. The entry-timing implication: there is no oversold set-up and no urgency; buying here means buying in the middle of an extended move with the 200-day 12% below you, so a routine mean-reversion pullback into the mid-$80s (the 50-day zone) is a realistic risk before the next leg. A break below ~$86.5 would be the first meaningful trend crack; a clean break above $92.5 opens the path toward the analyst $95-104 zone.

• Sector rotation and the defensive bid: with a 0.342 beta, KO has been the beneficiary of institutional money leaving AI-capex-exposed megacap tech for reliable cash generators. That is the reason the stock is up 26-28% YTD, and it is the single factor most likely to reverse if tech leadership returns - this is a flow-driven tailwind, not a fundamental one, and flows cut both ways.
• Interest rates and bond yields: a 2.57% dividend yield is below KO's historical yield, so the relative-value case versus Treasuries depends on where rates go. Falling rates support staples multiples; a backup in yields would make a 26.5x P/E harder to defend.
• FX translation: roughly half of revenue is non-US, so a weaker dollar mechanically inflates reported revenue and a stronger dollar creates a reported-revenue headwind even when organic growth is intact - a persistent source of guidance noise and one management flags regularly.
• Health regulation and sugar taxes: tightening labeling rules, sugar taxes, and marketing restrictions in developed markets are a permanent structural headwind that forces continued reformulation and portfolio shift toward zero-sugar and functional categories.
• Input cost and pricing-power tension: aluminum, PET resin, sugar, and freight remain background inflation risks. KO has so far used pricing to offset them without breaking demand (Q2 2026 volume +5%), but the growth mix is leaning on price/mix, and there is a limit to how much more price consumers will absorb.

• Q3 2026 earnings, expected late October 2026 (projected 2026-10-20 to 2026-10-27): the key question is whether the +5% global unit case volume from Q2 2026 is repeatable or whether it was a favorable comparison. Confirmation of ~5% organic revenue and full-year EPS tracking toward +9-10% would support the multiple; a volume slowdown would be the fastest route to de-rating.
• Closing of the Coca-Cola Beverages Africa divestiture in H2 2026: structurally margin-accretive, removing lower-margin bottling operations from the consolidated P&L and reinforcing the operating-margin improvement already visible (34.9% in Q2 2026).
• fairlife capacity ramp-up: the value-added dairy line is the highest-margin growth engine in the portfolio, and production scaling is a direct, incremental margin and revenue driver.
• Ongoing defensive flows and further analyst target revisions: with consensus at $95.75 and the high target at $104, continued PT increases during a tech-aversion regime can pull the price with them.

• Valuation/multiple risk is the dominant one. At 26.5x trailing earnings, 7.6x sales (24% above the 5-year average of 6.11x) and 10.5x book, there is very little cushion. This stock has already re-rated on defensive rotation; a rotation back into cyclicals or a single soft quarter could compress the multiple 10-15% even with earnings intact.
• Volume-versus-price mix. Recent growth has leaned heavily on pricing, and Q2 2026's +5% unit case volume is a high bar. If the consumer weakens, price increases stop working and volume elasticity turns negative - KO's own history shows volume is what breaks first in a slowdown.
• Foreign exchange and emerging-market exposure. With roughly half of revenue outside the US, a strengthening dollar is a direct, unhedgeable drag on reported results.
• Regulatory and health headwinds - sugar taxes, labeling mandates, and marketing restrictions on sugary drinks - remain a slow structural tax on the core sparkling business and require continuous portfolio reinvestment.
• Earnings-quality noise at the quarterly level. Q4 2025 showed operating income of $1.841B against net income of $2.271B, meaning large below-the-line items drove the quarter. That quarter distorts trailing YoY comparisons and is a reminder not to take any single quarter's margin at face value.

This is a good business at a full price, not a bargain. The fundamental inflection is real and recent - revenue growth swung from -1.5% YoY in Q1 2025 to +12.1% in Q1 2026 and +6.7% in Q2 2026, operating margins structurally stepped up from the low-20s in 2024 to ~35% in 2026, EPS is compounding at ~17% YoY, guidance was raised, accruals are negative (cash backs the earnings), and net debt of roughly $30.7B against ~$19.8B EBITDA (~1.6x) is a fortress balance sheet. But the market has already paid for that: +26-28% YTD, a 26.5x trailing P/E above its 25.4x 5-year average, and 7.6x sales versus a 6.11x norm. As of 2026-09-13 my own fair value work lands at $90.00 - about 2% above the $88.29 price. So: hold if you own it for the ~2.6% dividend and low-beta defense, but a fresh purchase here is a bet on continued defensives rotation, not on valuation. I would want the high-$70s to low-$80s (the 50-day/200-day zone) before calling it a buy.

I applied a 25x justified forward P/E - anchored on KO's own 25.4x 5-year average trailing P/E and a PEG near 1.5, which caps how much re-rating an 8-9% EPS grower deserves - to FY2027E EPS of ~$3.60 (FY2026E ~$3.33 compounding at management's guided 9-10% comparable EPS growth, then ~8% as the Africa divestiture drags reported revenue but lifts margin), giving 25 x 3.60 = $90.00. Cross-checked against cash: TTM FCF of ~$14.3B, growing ~6-7%, implies a fair equity value of $357-410B at a 3.9-4.2% FCF yield, or roughly $83-95 per share, with the $2.27/share dividend (2.57% yield) sitting comfortably inside that range. $90.00 is my own figure, ~2% above the 2026-09-13 price of $88.29 and well below the analyst consensus target of $95.75.